CORRESP 1 filename1.htm

 

AEGIS CAPITAL CORP.

810 Seventh Avenue

18th Floor

New York, NY 10019

 

May 1, 2015                      

 

VIA EDGAR

 

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Re: BiondVax Pharmaceuticals Ltd.

Registration Statement on Form F-1

Filed April 30, 2015

File No. 333-201283

 

Ladies and Gentlemen:

 

The undersigned, as the representative of the underwriters, hereby joins in the request of BiondVax Pharmaceuticals Ltd. to cancel the representative’s acceleration request submitted to the Securities and Exchange Commission on April 28, 2015.

 

  Very truly yours,
   
  AEGIS CAPITAL CORP.
   
  By: AEGIS CAPITAL CORP.
     
  By: /s/ Anthony Monaco
    Name: Anthony M. Monaco
    Title: Chief Compliance Officer